Top videos
Key facts
Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
The virus is transmitted through contact with the blood or other body fluids of an infected person - not through casual contact.
About 2 billion people worldwide have been infected with the virus and about 350 million live with chronic infection. An estimated 600 000 persons die each year due to the acute or chronic consequences of hepatitis B.
About 25% of adults who become chronically infected during childhood later die from liver cancer or cirrhosis (scarring of the liver) caused by the chronic infection.
The hepatitis B virus is 50 to 100 times more infectious than HIV.
Hepatitis B virus is an important occupational hazard for health workers.
Hepatitis B is preventable with a safe and effective vaccine.
-----------------------------------
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is a major global health problem and the most serious type of viral hepatitis. It can cause chronic liver disease and puts people at high risk of death from cirrhosis of the liver and liver cancer.
Worldwide, an estimated two billion people have been infected with the hepatitis B virus (HBV), and more than 350 million have chronic (long-term) liver infections.
A vaccine against hepatitis B has been available since 1982. Hepatitis B vaccine is 95% effective in preventing HBV infection and its chronic consequences, and is the first vaccine against a major human cancer.
The lasting physical and emotional effects of a stroke can take a large toll on patients as well as family members with many stroke survivors needing to learn how to walk, talk and perform basic daily activities all over again.
Learn more about certified electronic health record and comprehensive hospital information system (HIS), Paragon®, from McKesson. Working with Paragon can help you achieve Stage 1 meaningful use and other important guidelines.
Neuropathic pain: often difficult to treat. Palmitoylethanolamide (PEA) is a very special molecule, produced in our own body, against pain and chronic inflammation. PEA is available as supplement and as cream, and as dietfood for medical purposes in Italy and Spain. It has been explored since 1957 and has a clear analgesic and anti-inflammatory efficacy, and virtually no side effects. Meanwhile within the context of clinical trials 5000 patients have been using PEA, and its efficacy and safety has been documented in more than 400 scientific papers: http://palmitoylethanolamide4pain.com/about-2/ a website containing 400+ scientific articles on PEA in 6 different languages. The PEA datapool.